A phase I/II trial with vorinostat and trastuzumab in patients with metastatic HER2-positive breast cancer following progression on trastuzumab reported a disappointing median PFS of 1.5 months and a median OS of 9.3 months [20]. The gene discussed is ERBB2; the disease is breast cancer.